openPR Logo
Press release

Postherpetic Neuralgia Market Size in 7MM is expected to witness a major change in the study period 2019-2032, estimates DelveInsight

11-16-2023 03:01 PM CET | Health & Medicine

Press release from: DelveInsight

Postherpetic Neuralgia Market

Postherpetic Neuralgia Market

"The Postherpetic Neuralgia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Postherpetic Neuralgia pipeline products will significantly revolutionize the Postherpetic Neuralgia market dynamics"

The Postherpetic Neuralgia market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Postherpetic Neuralgia market size from 2019 to 2032. The report also covers current Postherpetic Neuralgia treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.

Key Takeaways from the Postherpetic Neuralgia Market Report
• The increase in market size is a direct consequence of an increasing number of Postherpetic neuralgia patients in the 7MM and an improvement in the understanding of postherpetic neuraglia in the recent decades, leading to growing awareness, improved management, better outcomes, and increase in R&D activity for developing new molecules.
• According to DelveInsight's analysis, Postherpetic Neuralgia is more prominent in females in comparison to males.
• The leading Postherpetic Neuralgia Companies working in the market include Daiichi Sankyo Co., SRL Medisearch Inc., Quintiles Inc., KAI Pharmaceuticals, Trident Clinical Research Pty Ltd, Grünenthal GmbH, Pfizer, Winston Laboratories, Xenon Pharmaceuticals Inc., Bausch Health Americas Inc., ZARS Pharma Inc., Lexicon Pharmaceuticals, Merck Sharp & Dohme LLC, Teva Pharamceuticals, Zalicus, and others.
• Promising Postherpetic Neuralgia Pipeline Therapies in the various stages of development include DS-5565, KAI-1678, Lidocaine, TRK-700, Pregabalin, Civamide Patch, XPF-002, Retigabine, SR419, HSK16149 20mg BID, LX9211, and others
• On March 2023, Shanghai SIMR Biotechnology Co., Ltd. announced a study of phase 2 clinical trials for SR419. This is a Phase II, international multicenter, double-blind, placebo-controlled, crossover study to assess the efficacy of SR419 in PHN subjects.
• On March 2023, Lexicon Pharmaceuticals announced a study of phase 2 clinical trials for LX9211. Evaluation of the efficacy of LX9211 compared to placebo in reducing pain related to postherpetic neuralgia over an 11 week assessment period.
• On May 2023, UCB Pharma announced a study of phase 2 clinical trials for SPM927/Lacosamide. The objective of the trial is to investigate the analgesic efficacy of SPM 927 in subjects with moderate to severe neuropathic pain due to Postherpetic Neuralgia (PHN).

Discover more about therapies set to grab major Postherpetic Neuralgia Market Share @ Postherpetic Neuralgia Market Size- https://www.delveinsight.com/report-store/postherpetic-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Postherpetic Neuralgia Overview
Postherpetic neuralgia is a type of neuropathic pain that persists for more than three months after the resolution of the acute phase of herpes zoster infection. It is characterized by intense, burning, stabbing, or shooting pain in the affected dermatome (area of the skin supplied by a single nerve).

Postherpetic Neuralgia Epidemiology Segmentation in the 7MM
• Total Postherpetic neuralgia Incident Cases
• Postherpetic neuralgia Gender-Specific Cases
• Postherpetic neuralgia Site-Specific Cases
• Postherpetic neuralgia Age-Specific Cases
• Postherpetic neuralgia Treated Cases

Download the report to understand which factors are driving Postherpetic neuralgia Epidemiology Trends @ Postherpetic neuralgia Epidemiological Insights- https://www.delveinsight.com/sample-request/postherpetic-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Postherpetic Neuralgia Market Insights
The duration of pain in postherpetic neuralgia can be highly variable, suggesting that multiple pathophysiological mechanisms may be involved. In addition, approximately 40% to 50% of patients with postherpetic neuralgia do not respond to any treatment, and other patients experience limited efficacy due to the inherent properties of the therapies. Treatment of Postherpetic neuralgia is often accompanied by intolerable side effects. SHRINGIX (GSK1437173A), a recombinant zoster vaccine, was approved for the prevention of herpes zoster (shingles). But as with any other vaccine, it is recommended for preventive use instead for the treatment of an acute event of herpes zoster like Postherpetic neuralgia.

Postherpetic Neuralgia Market Dynamics
The postherpetic neuralgia market dynamics is anticipated to change in the coming years due to the positive outcomes of the pipeline candidates during the developmental stage by key players, such as Lexicon Pharmaceuticals (LX9211), Confo Therapeutics (CFTX-1554) etc. All these therapies can create a positive shift in postherpetic neuralgia market size during the forecast period (2023-2032).

To know more about Postherpetic Neuralgia Treatment options, visit @ Postherpetic Neuralgia Drugs- https://www.delveinsight.com/sample-request/postherpetic-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Postherpetic Neuralgia Market Outlook
The Postherpetic Neuralgia market outlook reflects a dynamic landscape marked by evolving therapeutic approaches and a growing emphasis on patient-centric care. PHN, a debilitating condition arising from the reactivation of the varicella-zoster virus, continues to pose significant challenges to both patients and healthcare providers. However, advancements in medical research and innovative treatments have offered renewed hope.

Postherpetic Neuralgia Treatment Market
The Postherpetic Neuralgia Treatment Market refers to the industry segment dedicated to addressing the complex and often debilitating condition known as Postherpetic neuralgia (PHN). PHN is a chronic pain syndrome that can develop following an outbreak of herpes zoster, commonly known as shingles.

Learn more about the Postherpetic Neuralgia Pipeline Therapies in clinical trials @ Postherpetic Neuralgia Market Landscape- https://www.delveinsight.com/sample-request/postherpetic-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Postherpetic Neuralgia Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Postherpetic Neuralgia Companies- Daiichi Sankyo Co., SRL Medisearch Inc., Quintiles Inc., KAI Pharmaceuticals, Trident Clinical Research Pty Ltd, Grünenthal GmbH, Pfizer, Winston Laboratories, Xenon Pharmaceuticals Inc., Bausch Health Americas Inc., ZARS Pharma Inc., Lexicon Pharmaceuticals, Merck Sharp & Dohme LLC, Teva Pharamceuticals, Zalicus, and others.
• Postherpetic Neuralgia Pipeline Therapies- DS-5565, KAI-1678, Lidocaine, TRK-700, Pregabalin, Civamide Patch, XPF-002, Retigabine, SR419, HSK16149 20mg BID, LX9211, and others.
• Postherpetic Neuralgia Market Dynamics: Postherpetic Neuralgia Market Drivers and Barriers
• Postherpetic Neuralgia Market Access and Reimbursement, Analyst Views, Unmet Needs

Discover more about Postherpetic Neuralgia Drugs in development @ Postherpetic Neuralgia Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/postherpetic-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Executive Summary of Postherpetic Neuralgia
3. Competitive Intelligence Analysis for Postherpetic Neuralgia
4. Postherpetic Neuralgia: Market Overview at a Glance
5. Postherpetic Neuralgia: Disease Background and Overview
6. Patient Journey
7. Postherpetic Neuralgia Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Postherpetic Neuralgia Unmet Needs
10. Key Endpoints of Postherpetic Neuralgia Treatment
11. Postherpetic Neuralgia Marketed Products
12. Postherpetic Neuralgia Emerging Therapies
13. Postherpetic Neuralgia: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Postherpetic Neuralgia
17. KOL Views
18. Postherpetic Neuralgia Market Drivers
19. Postherpetic Neuralgia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Get in touch with our Business executive @ Postherpetic Neuralgia Market Drivers and Barriers- https://www.delveinsight.com/sample-request/postherpetic-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Important Published Links-

https://treadmill.mn.co/posts/45459156
https://chineseintheus.mn.co/posts/parkinsons-disease-market-size-outlook-and-forecast
https://wear.net/dennydones9/
https://productinn.mn.co/posts/parkinsons-disease-market-outlook-and-forecast-report-2032
https://justchatting.mn.co/posts/45460636
https://expressyourcurve.mn.co/posts/45460860
https://clinalleve.mn.co/posts/parkinsons-disease-market-size-outlook-and-forecast-2032
https://nhattao.com/members/user6331540.6331540/
https://seedly.sg/profile/denny-dones/
https://note.com/denny_dones/n/n489e5dd1ff1a
https://www.storeboard.com/JohnSmith-5965202
https://doodleordie.com/profile/dennydones99
https://macro.market/company/delveinsight-business-research
https://pantip.com/profile/7306022#topics
https://allmylinks.com/dennydonesusa
https://uconnect.ae/read-blog/4382
https://blacksnetwork.net/post/102497_herpetic-keratitis-is-a-condition-that-affects-the-eye-and-is-caused-by-the-herp.html
https://ekonty.com/-dennydones99
https://app.wedonthavetime.org/posts/03e285b9-e449-4c96-b257-8cb7a2b74243
https://www.weddingbee.com/members/dennydones99/
https://community.storytellingwithdata.com/members/me/gallery
https://participer.valdemarne.fr/profiles/denny_dones/activity
https://elderassociation.mn.co/posts/45117025
https://www.domestika.org/en/dennydones99
https://nxgen.mn.co/members/19995548
https://www.laclt.com/profile/ybhardwaj/profile
https://stemfemmes.mn.co/posts/emerging-trends-in-managing-hot-flashes-in-the-prostate-cancer-market
https://network-91053.mn.co/posts/45119865
https://autism-support.mn.co/posts/understanding-hot-flashes-in-prostate-cancer-market-size-and-outlook-2032
https://jasa-seo.mn.co/posts/45120226
https://lapp.unl.edu.ec/profiles/dennydones99/activity?locale=en
https://imarticus.org/skillenza/user/dennydones9
https://oppathingzz.mn.co/members/20019648
https://findaspring.org/members/dennydones9/
https://www.poeticous.com/yashveer-bhardwaj
https://git.disroot.org/dennydones9
https://kuula.co/profile/havensmith
https://artmight.com/user/profile/3082810
https://www.credly.com/users/denny-dones/badges
https://quantum-buoyancy.mn.co/posts/axillary-hyperhidrosis-market-size-and-outlook-delveinsight
https://freeline.mn.co/posts/45202136
https://3dwarehouse.sketchup.com/user/0e9f9584-794e-4467-ac59-79db9efbadd9/Denny-Dones
https://www.hackster.io/dennydones9
https://letterboxd.com/dennydones9/
https://ko-fi.com/dennydones9
https://wakelet.com/@DennyDones813
https://onedio.com/profil/dennydones9
https://www.lyrics.com/user/349564/dennydones9#google_vignette
https://hypothes.is/users/dennydones9
https://shivambhu-hut.mn.co/posts/exploring-the-axillary-hyperhidrosis-market-innovations-treatments-and-future-prospects
https://zumvu.com/dennydones9/
https://onlyfans.com/dennydones9
https://maker.wiznet.io/dennydones9
https://collab.sundance.org/people/Denny-Dones-1699939772
https://insurtechasia.mn.co/posts/45403575
https://meganto-lottery.mn.co/posts/45403650
https://ylimun.mn.co/posts/45403740
https://network-79379.mn.co/posts/45404061
https://acatpg.mn.co/posts/45404422
https://brooklynneo.mn.co/posts/45404495
https://ucat-bootcamp.mn.co/posts/45404540
https://coding-playground.mn.co/posts/45404600
https://living-word-network.mn.co/posts/45404653

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Postherpetic Neuralgia Market Size in 7MM is expected to witness a major change in the study period 2019-2032, estimates DelveInsight here

News-ID: 3290436 • Views:

More Releases from DelveInsight

Insulin Resistance Pipeline Insight 2025: Pipeline Drugs, Metabolic Pathway Modulators, and Novel Therapeutics Redefine Future Care | DelveInsight
Insulin Resistance Pipeline Insight 2025: Pipeline Drugs, Metabolic Pathway Modu …
DelveInsight's "Insulin Resistance - Pipeline Insight, 2025" explores over 10+ therapies in development for insulin resistance, a metabolic condition strongly linked to type 2 diabetes, obesity, and cardiovascular disease. Despite lifestyle modification and insulin-sensitizing drugs like metformin being mainstays of management, many patients continue to face poor glycemic control and associated complications, underscoring the need for more effective insulin resistance treatments. The insulin resistance pipeline is broadening with next-generation therapies targeting
Uveal Melanoma Pipeline Insight 2025: 30+ Pipeline Drugs, Targeted Therapies, and Immuno-Oncology Strategies Drive Innovation | DelveInsight
Uveal Melanoma Pipeline Insight 2025: 30+ Pipeline Drugs, Targeted Therapies, an …
DelveInsight's "Uveal Melanoma - Pipeline Insight, 2025" explores over 30+ therapies in development for uveal melanoma, a rare and aggressive intraocular malignancy with high metastatic potential, most commonly to the liver. Despite surgery and radiotherapy being standards for localized disease, patients with metastatic uveal melanoma face limited systemic treatment options, creating significant unmet needs in the uveal melanoma treatment landscape. The uveal melanoma pipeline is diversifying with next-generation targeted therapies, including
Peptic Ulcers Pipeline Insight 2025: Emerging Therapies and Clinical Trials Shaping Next-Generation Peptic Ulcer Disease Treatments | DelveInsight
Peptic Ulcers Pipeline Insight 2025: Emerging Therapies and Clinical Trials Shap …
DelveInsight's "Peptic Ulcers - Pipeline Insight, 2025" examines over 8+ therapies in development for peptic ulcer disease, a condition affecting millions worldwide with peptic ulcer disease symptoms such as abdominal pain, bloating, nausea, and gastrointestinal bleeding. Despite widespread use of existing peptic ulcer disease treatments, including proton pump inhibitors, H2 blockers, and antibiotics for H. pylori eradication, patients with recurrent or complicated peptic ulcers continue to face significant unmet needs,
Vaso-Occlusive Crisis in Sickle Cell Disease: Emerging Therapies, Clinical Trials, and Pipeline Innovations Shaping the Future of Treatment - 2025 | DelveInsight
Vaso-Occlusive Crisis in Sickle Cell Disease: Emerging Therapies, Clinical Trial …
DelveInsight's "Vaso-Occlusive Crisis (VOC) Associated With Sickle Cell Disease - Pipeline Insight, 2025" provides an in-depth analysis of emerging therapies targeting vaso-occlusive crisis (VOC), a severe and recurring complication of sickle cell disease. Despite current standards of care, including hydroxyurea, patients continue to experience frequent vaso occlusive sickle cell crisis, underscoring the urgent need for effective interventions in sickle cell anemia vaso occlusive crisis treatment. The VOC pipeline is diversifying with

All 5 Releases


More Releases for Postherpetic

Postherpetic Neuralgia Market Trends, Treatments, and Growth Opportunities
Postherpetic neuralgia (PHN) is a debilitating complication of shingles (herpes zoster), causing chronic nerve pain that significantly affects patients' quality of life. The Postherpetic Neuralgia Market has gained substantial attention in recent years, as healthcare providers, pharmaceutical companies, and research organizations work toward effective pain management solutions. The growing prevalence of shingles, aging populations, and advances in therapeutic interventions underscore the critical need for innovative PHN treatments. Download Full PDF Sample
Postherpetic Neuralgia (PHN) Market: Major Trends Reshaping the Future of the In …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Will the Postherpetic Neuralgia (PHN) Industry Market Size Be by 2025? The market for postherpetic neuralgia (phn) has witnessed significant growth lately. The market, which was worth $0.72 billion in 2024, is projected to increase to $0.77 billion by 2025, showcasing a compound annual growth rate (CAGR) of
Postherpetic Neuralgia Market Is Going to Boom | Major Giants Pfizer, Teva, Glax …
HTF MI just released the Global Postherpetic Neuralgia Market Study, a comprehensive analysis of the market that spans more than 143+ pages and describes the product and industry scope as well as the market prognosis and status for 2025-2032. The marketization process is being accelerated by the market study's segmentation by important regions. The market is currently expanding its reach. Major companies profiled in Postherpetic Neuralgia Market are: Pfizer, Teva, GlaxoSmithKline,
Postherpetic Neuralgia Pipeline, Therapeutics Assessment, Clinical Trials, Drugs …
DelveInsight's, "Postherpetic Neuralgia Pipeline Insight 2024" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Postherpetic Neuralgia pipeline landscape. It covers the Postherpetic Neuralgia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in
Postherpetic Neuralgia Treatment Drugs, Pipeline Insights Report 2024
DelveInsight's, "Postherpetic Neuralgia Pipeline Insight 2024" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Postherpetic Neuralgia pipeline landscape. It covers the Postherpetic Neuralgia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in
Postherpetic Neuralgia Market Forecast: Navigating Growth, Trends, and Key Playe …
"Posrpetic Neuralgia Market Was Valued At US$ 803 Million In 2024 And Is Projected To Grow At A Cagr Of 5.6% To Reach US$ 1320.9 Million By 2034.". With thorough company profiles, recent developments, and other information, the Postherpetic Neuralgia Market Report provides an in-depth analysis of major trends, motivating reasons, obstacles, segmentation, regulatory policies, and important players. The Postherpetic Neuralgia Market Report offers a thorough synopsis of the product portfolio,